Stay updated on Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check59 days agoChange DetectedThe webpage has been updated to reflect a new version of the clinical trial information, including the addition of specific cancer types and identifiers, while removing detailed descriptions of the study's purpose and objectives.SummaryDifference53%
- Check74 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.